Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Adv Nanobiomed Res. 2021 Jan 18;1(3):2000063. doi: 10.1002/anbr.202000063

Advanced nanobiomedical approaches to combat COVID-19

Halle Lutz 1,2, Kristen D Popowski 1,2, Phuong-Uyen Dinh 1,2, Ke Cheng 1,2,3,4,*
PMCID: PMC7917381  NIHMSID: NIHMS1664586  PMID: 33681865

Abstract

New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus SARS-CoV-2 in December 2019 has already infected over 65 million people and caused over 1.5 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the disease COVID-19. The different vaccine types investigated for the prevention of COVID-19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adeno-associated viruses, virus-like particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVID-19 in terms of vaccines and therapeutics.

Keywords: COVID-19, SARS-CoV-2, nanomedicine, exosome, vaccine, therapeutic

1. Introduction

Coronaviruses are single-stranded positive-sense RNA viruses ranging 80nm to 120nm in diameter.1-3 Severe acute respiratory syndrome coronavirus, or SARS-CoV-1, was the first highly virulent human coronavirus to appear in 2002 with a mortality rate of 9.6%.1,3,4 When Middle East respiratory syndrome coronavirus, or MERS-CoV, produced an epidemic with a high mortality rate of 34.0%,5 being of the same coronavirus family, an inactivated SARS-CoV-1 vaccine was tested. However, it was found to have little effect on mice and ferrets, and it was determined that a new vaccine was required for protection from MERS-CoV.6 In December 2019, a highly virulent novel severe acute respiratory coronavirus, SARS-CoV-2, was identified. Symptoms ranged among confirmed cases from asymptomatic to severe acute respiratory distress syndrome, multiple organ failure, and even death.7 It quickly became clear that the elderly or those with comorbidities were more affected and contribute the most to the mortality rate, currently estimated to between 2 and 4%.8 In March 2020, the World Health Organization declared the coronavirus disease of 2019 (COVID-19) a pandemic. Since then, an intense and thorough global research effort towards understanding this pathogen for vaccines and treatments has been conducted. So far, the preventative measures imposed have included requiring masks, encouraging physical distancing, and imposing lockdowns. While these measures have been effective in reducing the transfer of the virus and thereby reducing mortality due to COVID-19, the global economy has been greatly impacted and producing a vaccine is critical. Early research discovered that SARS-CoV-2 used the same receptor as SARS-CoV-1 for viral entry, angiotensin converting enzyme 2 (ACE2). Decorating the surface of SARS-CoV-2 are spike proteins with two subunits, S1 and S2. On S1 is a receptor binding domain (RBD), which is the part of SARS-CoV-2 that binds to the ACE2 receptor for entry into host cells.9 This knowledge has provided researchers with a target for vaccination for the prevention of COVID-19.

Vaccination is understood to be one of the most effective methods for maintaining population health among both humans and livestock since infectious diseases are a major cause of death across all ages.10 Vaccines are a way of inducing the body to produce memory cells that make protective antibodies against infectious diseases. When the body does encounter the virus, the body can respond and eliminate the virus faster than it would have without a previous vaccination because the body already has memory cells to create the neutralizing antibodies. Vaccines are incredibly important as new infectious diseases emerge and threaten lives, standards of living, and the economy.7,9,10 Despite their necessity, vaccines are often difficult to produce, produce in high enough quantity, and deliver at a reasonable cost.11 Moreover, conventional vaccines, such as whole inactivated virus vaccines, typically have less efficacy due to inducing a weaker immune response. So far, only one human disease has successfully reached this designation, smallpox, and it was due to a global vaccination effort. A thorough understanding of the parent virus is critical and to obtain an adequate level of comprehension, BSL-3 or −4 facilities are required to thoroughly study SARS-CoV-2.10 Vaccine development is critical to begin battling COVID-19, but while vaccine candidates are tested, millions of people globally are suffering from COVID-19. As of 06 December 2020, there have been over 65 million confirmed cases and over 1.5 million deaths from COVID-19, and there is now only one approved treatment, Remdesivir.8,12 So far, most treatments have been symptomatic, using mechanical ventilation or extracorporeal membrane oxygenation for patients, but it is clear that a COVID-19 specific treatment is needed. Nanobiomedical approaches to vaccine development—focusing on preventing viral entry or replication with self-assembled protein nanoparticles for example—and therapeutics are particularly promising because they are able to produce stronger responses with greater specificity for a longer period of time.13,14 This review aims to describe the potential of nanobiomedical vaccine types and promising therapeutics for addressing SARS-CoV-2.

3. Nanobiomedical approaches to COVID-19 vaccines

3.1. Whole inactivated viruses for infectious diseases

Previously, vaccines for infectious diseases had primarily been live attenuated viruses, which posed a safety concern since the virus could reactivate and result in vaccine-derived disease.6,11 Inactivated vaccines were first administered as vaccines in the late 1800s to protect against cholera, followed by diphtheria—both of which are bacterial pathogens. In the 1900s, inactivated vaccines were considered for viruses,15 and in 1936, the first whole inactivated vaccine (WIV) became available for the influenza virus, leading the way for other infectious diseases.16,17 The main advantage of WIVs was that they worked much more safely, while maintaining antigen presentation and stability for the immune system to respond.4 Another advantage is that with enough knowledge about the virus and replication process, large quantities of the virus can be quickly produced and therefore, made quickly available.18 However, WIVs are not safe to produce and require culturing the infectious agents in at least BSL-3 facilities, posing a risk to WIV developers.15,19,20 Frequently, mammalian cells, such as Vero, are used to culture the viruses.18,20 To inactivate, live viruses are exposed to ultraviolet (UV) irradiation, formalin, beta-propiolactone (BPL), or a combination of these to effectively damage the genetic material to prevent viral replication.18

To create a SARS-CoV-1 WIV, Spruth et al. utilized a double-inactivation process of formalin and UV irradiation, having considered the virulence of SARS-CoV-1 and past reports of inactivation failures when only using one inactivation method. Despite the double-inactivation, Spruth et al. successfully demonstrated that the WIV maintained its antigenic structure and immunogenicity.18 Unfortunately, in contrast, Bolles et al. demonstrated that double-inactivated WIVs have the potential to actually cause a hypersensitive response, emphasizing the importance of careful vaccine design.21 To overcome this, an adjuvant is recommended, which will stimulate a T cell response.22 WIVs have been criticized for their poor immunogenicity and the subsequent necessary booster immunizations, but they have consistently been shown to produce neutralizing antibodies.10,19 When studying a BPL-inactivated SARS-CoV-1 WIV in hamsters, Roberts et al. found that even low levels of neutralizing antibodies conferred protection.4 In further support of WIV efficacy, the poliovirus epidemic in the United States was significantly attenuated by an inactivated polio vaccine. Before another vaccine candidate had been approved, the polio WIV was responsible for reducing paralytic polio by about 94% from 13.9 cases per 100,000 people to a mere 0.8 cases per 100,000 people.15 Since the poliovirus epidemic, the only other WIVs to become commercially available are for Hepatitis A,23 rabies,24 and influenza virus.25 Still, WIVs continue to be studied as potential vaccine candidates for old and emerging viral diseases, including the SARS and MERS coronaviruses. Until the viruses are completely eliminated, different vaccination techniques to combat these viruses will continue to be investigated, but for the COVID-19 pandemic, SARS-CoV-2 WIVs may be a temporary solution. Already, Gao et al. has shown that after three SARS-CoV-2 WIV immunizations, rhesus macaques demonstrated complete protection when challenged with SARS-CoV-2.26 In fact, Sinovac’s CoronaVac is a WIV for immunization against SARS-CoV-2 and has entered a Phase III clinical trials, having previously shown safety and efficacy in a randomized, double-blind Phase I/II clinical trial.27

3.2. Adeno-associated virus for infectious diseases

In 1965, adeno-associated virus, or AAV, was discovered in a sample of adenovirus, and characterized as a replication-defective Parvoviridae virus that was non-enveloped and contained either positive- or negative-sense single-stranded DNA.28-30 The genome contains genes for replication, the capsid proteins, and assembly with inverted terminal repeats at the beginning and end.28-31 AAV is a safe technology since it lacks the ability to replicate without the genes of a helper virus, such as an adenovirus, and even in the presence of an adenovirus, AAV has not been associated with any disease.31,32 In fact, Naso et al. notes that most people have already been exposed to an AAV variant but no noticeable symptoms have resulted.30 Therefore, it has been mainly used as a delivery system for either gene therapy or antigens for immunogenicity.28-34 Gene therapy has focused on cancer and neurodegenerative diseases, using recombinant AAV, in which the viral genetic code is replaced with a gene of interest.31,35 However, the replacement gene must be similar or smaller than the 4.7 kb AAV genes or the stability of the recombinant AAV will suffer.28-31 Furthermore, AAV production is difficult to scale-up, since even though mammalian and insect cells can produce high quantities in a short amount of time, the AAV replication gene kills the cells, making it an expensive therapy.30 So far, only two AAVs have been commercially approved, but each cost approximately one million dollars for a single treatment.28-31 Still, AAV has been shown to enable targeted delivery and expression to specific tissues as a result of the AAV variant combined with the tissue-specific promoter sequence, and over two hundred clinical trials using AAVs are in progress.30

AAV has been criticized as a vaccine option due to its naturally poor immunogenicity that is furthered by pre-existing immunity due to a previous exposure. Furthermore, Lin et al. explains that at least two AAV immunizations must occur for a detectable antibody response in human immunodeficiency virus 1 (HIV-1), and considering the current AAV therapy costs, it is not likely feasible.28 However, antigens bound to the surface or the gene an AAV carries can result in antigen-presenting cell uptake and recruit B and T cells for a strong immune response and different expression systems are still being explored.30 In terms of immunogenicity, an AAV carrying a gene coding for a neutralizing antibody can be used to protect against pathogenic infections.31 In fact, Demminger et al. used a recombinant AAV vector carrying an influenza hemagglutinin expression cassette to show that broadly-reactive neutralizing antibodies were induced and protected against influenza viruses with different mutations.34 In addition, Yusuf et al. has demonstrated that recombinant AAV-based immunization after adenovirus priming was able to induce a long-lasting antibody response in a mouse model.32 Recombinant AAV technology has been considered for SARS-CoV-1 with promising results. Du et al. found that intranasal vaccination of a recombinant AAV encoding the receptor-binding domain of the SARS-CoV-1 spike protein induced a strong systemic humoral response that was comparable to intramuscular vaccination. Unfortunately, the intranasal administration resulted in a shorter immune response than intramuscular vaccination, indicating that multiple immunizations would be necessary, again making production costs a consideration.33 Considering the scale of the COVID-19 pandemic, for AAV vaccination to become a truly viable option as a COVID-19 therapeutic, an inexpensive yet high-quality production method must be identified. Two noteworthy COVID-19 AAVs are those created by the Gamaleya Research Institute of Epidemiology and Microbiology and AstraZeneca, both of which seek to immunize against the SARS-CoV-2 spike protein.36,37 AstraZeneca has entered a Phase III clinical trial, but not yet reported efficacy, while the Gamaleya Research Institute of Epidemiology and Microbiology reported that their adenoviral-based vaccine, Gam-COVID-Vac or Sputnik V, has 92% efficacy from 20 patients in their Phase III clinical trial.38,39

3.3. Virus-like particles for infectious diseases

Virus-like particles, or VLPs, were first described in 1948 when studying adenocarcinoma,40 and in 2006, VLPs gained recognition when it was commercially approved as a synthetic vaccine to protect against the human papillomavirus (HPV).41 Despite no longer being a new technology, VLPs have recently seen a rapid expansion for the treatment and prevention of both noninfectious and infectious diseases for humans and livestock. VLPs are typically 20 to 100nm, mimicking the size of the parent virus and allowing VLPs to enter the lymph nodes to induce B cell activation, antigen-presenting cell (APC) uptake, and subsequently, T cell activation.42,43 VLPs are composed of one or more repeating viral capsid and structural proteins,11 meaning that different VLPs can be created from a single virus if different capsid proteins or different combinations of capsid proteins are used.44,45 For instance, human papillomavirus, or HPV, has two capsid proteins, L1 and L2. Current commercially available HPV vaccines are VLP-based and built with the L1 capsid antigen, leaving the possibility of an L2-based VLP to overcome the type-restriction protection the L1-based VLPs face.45 Because VLPs carry the same antigens as the parent virus, they induce the same immunogenicity.46 In fact, because the antigen is repeated so many times in such high density, VLPs can actually amplify their immunogenicity in comparison to the parent virus.45 VLP activation of the immune system is strong enough to provide protection for years, with the first VLP-based vaccine for the Hepatitis E virus conferring protection for almost five years after the initial vaccination and VLP-based vaccines for human papillomavirus (HPV) offering protection for up to a decade.11,45 The chief difference from the parent virus is that VLPs lack the genetic core that allows viruses to replicate, making VLPs a safer vaccine alternative than current options.47,48 However, VLPs are not just being studied because they are a safe and effective compared to virus-related vaccines. There have also been investigations into how VLPs can be used as nanoparticles for targeted delivery of drugs,44 gene therapy,47 and the treatment of non-infectious diseases such as cancer,43,45,48 neurodegenerative diseases,49,50 hypertension,51-53 nicotine addiction,54 diabetes,55 and even allergies.50,56

VLPs are relatively inexpensive to produce, but the production process itself is complicated.47 VLPs self-assemble and can range from a simple single-layered VLP to a complex multi-layered VLP composed of multiple proteins or decorated with various glycoproteins, depending on the parent virus and the purpose of the VLP. Once thorough investigation into the parent virus is concluded, only BSL-2 facilities are necessary for VLP construction. The size and geometry of VLPs are important for B cell activation and long-lasting antibody responses.42 The addition of peptides to carrier coat proteins cannot interfere with the ability to self-assemble.47 The recombinant proteins that self-assemble into VLPs can be expressed in several host systems, including bacteria, yeast, insects, plants, mammalian cells, and even cell-free systems. 10,11,47,57,58 In addition, the same VLP can be produced in different host systems.45

VLPs can be modified to further increase immunogenicity by adding antigens or epitopes with genetic fusions or chemically conjugating to pre-formed VLPs.10,11,44 Furthermore, VLPs can be modified to have an increased diversity of antigens.42 Other modifications are necessary for increasing the stability of VLPs in terms of temperature, pH, and time.43,44,47 However, the modifications made must be done with careful consideration, because VLPs’ ability to self-assemble and stability depend on the conformation of the VLP. Introducing too many components has the potential to render the VLP unable to assemble and thus, ineffective.42 In fact, Boigard et al. found that the temperature at which the VLP is produced can also impair VLP efficacy. When studying dengue VLPs in a mouse model, only VLPs produced at 31°C, as opposed to 37°C, were able to generate neutralizing antibodies.59 Computational models that study protein folding are recommended to save money and time and ultimately increase the success rate of VLPs becoming candidates for clinical trials.10 Despite the difficulties of producing VLPs, VLPs are still considered easier to produce than their native virus.

There are multiple procedures after producing a VLP to ensure its purity and safety, as well as to ensure its function. Some procedures used for VLP purification are chromatography,44,47,57 sucrose density gradients,1,6,57 and centrifugation. To confirm purity, SDS-PAGE is frequently used.10,11,53 Steps required for VLP characterization are as specific as identifying the primary amino acid sequence,11 molecular weight by mass spectrometry50 and Western blots,1,6 and determining the isoelectric point.11,47 To confirm VLP structure, transmission electron microscopy and cryo-electron microscopy are typically employed.1,10,47 Immunogenicity testing is assessed with enzyme-linked immunosorbent assays (ELISAs),1,6,11,47,57 probing with monoclonal antibodies,11 and immunodiffusion tests10, before an appropriate preclinical animal model is used to accurately predict the safety and efficacy of the VLPs.6,10

Some of the viruses that VLPs have been used for include HPV, influenza viruses, flaviviruses, and coronaviruses. HPV has been of particular interest because these double-stranded DNA viruses are the primary cause of cervical cancer, which is the third deadliest cancer for women. As mentioned earlier, the currently approved HPV vaccines were constructed from only one of the two HPV capsid proteins. Therefore, even though they are effective for up to ten years, the use of a single capsid protein prevents the vaccines from offering general protection against all types of HPV.45 The influenza viruses present another enduring viral challenge since hemagglutinin, the glycoprotein responsible for entry, rapidly mutates.60 As a result, new influenza vaccines must be made each year to maintain protection from the new changes in hemagglutinin conformation. Even then, vaccine production lags behind influenza virus changes.61 It has been suggested that using multi-structural VLPs as vaccines, instead of the classic influenza vaccine method using embryonated chicken eggs, could produce immune responses that would defend against the different forms of influenza. 34,60,62,63 More investigation is necessary, but influenza VLPs have the potential to save time and labor spent continuously developing subtype- and strain-specific influenza vaccines. Even as VLPs are used to address challenges that plagued for centuries, they are also being considered as novel infectious diseases emerge. Flaviviruses have grown as a global health concern due to the expanding human population into tropical and subtropical regions, where mosquitos carry and transmit flaviviruses.64,65 Flaviviruses are single-stranded positive-sense RNA viruses that include dengue virus, West Nile virus, and Zika virus. 26,57,64,65 Flavivirus VLPs have been demonstrated to produce strong, long-lasting immunogenicity and many have been brought to clinical trials, with Zika virus and chikungunya VLP vaccines currently in Phase 2.66 Among emerging infectious diseases are coronaviruses, and in December 2019, coronaviruses were brought to world attention again as the third highly infectious and deadly novel coronavirus in two decades appeared.

Since the SARS-CoV-1 outbreak, many vaccine candidates have been created with the expectation of another outbreak, one of which was a VLP produced by Lu et al., which was composed of the spike, membrane, and envelope proteins. Lu et al. tested the immunogenicity of their VLP and found that only four subcutaneous immunizations over the course of a month produced high immunogenicity with increased interferon-gamma production and T helper type 1 (Th1) cell activity. In fact, the antibodies produced were able to neutralize up to 90% of the SARS-pseudotypes.1 With the advent of MERS-CoV, Wang et al. produced a VLP similar to the aforementioned SARS-CoV VLP consisting of spike, envelope, and membrane proteins. When non-human primates were immunized with the MERS-CoV VLP, they found that immunization successfully produced high titers up to eight weeks after immunization and that IFN-gamma production was increased.6 Further exploring the application of VLPs for coronaviruses, Chen et al. created and studied a VLP decorated with avian infectious bronchitis virus (IBV). Covering gold nanoparticles with IBV spike protein, the VLP effectively delivered the antigens to the lymph nodes and resulted in increased IFN-gamma levels. Clinical scores were also reduced in the chickens that received the IBV-VLP as opposed to free protein or the inactivated virus.67 Therefore, VLPs have great potential to become an effective COVID-19 vaccine.

3.4. Lipid nanoparticles for mRNA vaccine delivery

Lipid nanoparticles, or LNPs, carrying mRNA recently emerged in the 1990s as safe, efficient, easy to manufacture, and scalable vaccination options.9,68 Since then, an mRNA-LNP has not yet been made commercially available, but an RNAi-LNP, Onpattro, was recently approved for polyneuropathy.69 mRNA can be either non-replicating or self-replicating, with the classification primarily depending on whether the nucleosides were modified.68,70 As for the LNPs, they can be composed of a lipid monolayer or a bilayer. mRNA-LNPs are administered by injection, either intramuscular or intradermal, and travel to enter the lymph nodes where mRNA-LNPs are then taken up by antigen presenting cells. Once the mRNA enters the cytoplasm, the host cell’s machinery is used to translate the corresponding protein and the protein expression activates B and T cells.9,68 mRNA-LNPs have been so effective in causing potent immunogenicity and long-lasting neutralizing antibody protection that only one or two doses have been needed to protect against infectious diseases in flavivirus,71 HIV-1,72 influenza,63 and SARS-CoV-22,9,70 animal models. One of the reasons mRNA-LNPs have such high efficacy is the stability of the mRNA due to structural modifications and encapsulation within a nanoparticle that protect it from degradation.9 Moreover, mRNA-LNPs are flexible: for instance, a Zika virus mRNA platform was adapted for a different flavivirus, Powassan virus, and was able to produce a strongly immunogenic response.73 Still, mRNA-LNPs are not without drawbacks, one of which involves production of antibodies that protect against one disease but may also increase susceptibility to another disease. This effect was observed with Zika virus mRNA-LNPs that increased dengue virus infection.71

The high production rate of mRNA-LNPs is particularly attractive when considering the global impact of the SARS-CoV-2 pandemic, since it means an mRNA-LNP vaccine would be both affordable and easily distributed. Currently, mRNA-LNPs are considered the forerunner for a SARS-CoV-2 vaccine, as Moderna has entered a Phase III clinical trial with an mRNA-LNP vaccine encoding the spike protein, mRNA-1273.2,9 Many other research groups have also produced their own SARS-CoV-2 mRNA-LNP, exploring different targets from just the receptor-binding domain to the entire spike protein, such as BioNTech/Pfizer’s BNT162b2, which has also entered a Phase III clinical trial.74 Some are considering other characteristics of a SARS-CoV-2 vaccine that would be important in addition to producing a high titer of neutralizing antibodies such as thermostability. Zhang et al. not only created a SARS-CoV-2 mRNA-LNP that demonstrated complete protection in a mouse model, but also created a SARS-CoV-2 mRNA-LNP that was stable when stored at room temperature for a week.2

4. Nanobiomedical approaches to COVID-19 therapeutics

4.1. Exosomes as a therapeutic and drug delivery platform

Exosomes are a type of extracellular vesicle typically 30 to 100nm in diameter that are released by cells.75 Originally thought to be carrying cell waste, exosomes were not considered for any application until recently when they were discovered to carry DNA, RNA, and proteins for cell-cell signaling.76 Natural exosomes have demonstrated their regenerative potential in a variety of diseases,77 but especially in lung diseases, both acute and progressive such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.5,78,79 In fact, the beneficial effects of mesenchymal stem cell (MSC) transplants have been largely attributed to their exosomes.5,75 Furthermore, unlike MSCs, exosomes are very stable, and, though still difficult and time-consuming, easier to scale up to necessary dosage with bioreactors.6,7,65 Exosomes are also produced by all cells and are present in almost all biofluids.75,12 Though there are concerns that exosomes package, deliver, and thus, amplify viral load throughout the body, the low immunogenicity of exosomes means that using exosomes from a healthy, uninfected source to combat COVID-19 should be safe and not cause adverse events.12 In May 2020, a Phase I clinical trial was completed, successfully demonstrating the safety and efficacy of bone marrow MSC exosomes for treating COVID-19, in which all patients responded positively with clinical improvement.80 In July 2020, a group from Ruijin Hospital, China completed a Phase I clinical trial to determine the safety and efficacy of adipose MSC exosomes in treating COVID-19-associated pneumonia.81 This same group has also begun a Phase I clinical trial focusing on applying MSC exosomes as a treatment for acute respiratory distress syndrome (ARDS), another lung disease closely tied to COVID-19.82 Since exosomes have parent cell-specific functions based on their cargo and membrane proteins, our group developed lung spheroid cells to study their effect in lung disease models.83,84 We found that not only are lung spheroid cells (LSCs) more effective than MSCs at attenuating bleomycin-induced pulmonary fibrosis, but also that the LSC exosomes attenuated bleomycin and silicosis pulmonary fibrosis in mouse models.79 Studying the therapeutic effect of LSC exosomes in COVID-19 and comparing it to bone marrow MSC exosome results are the next logical steps.

Exosomes can also be engineered to modify their cargo or the proteins in their lipid membrane, therefore enabling exosome functions to be altered. For instance, exosomes have been modified to display the tumor necrosis factor-alpha receptor 1 as a way of reducing inflammation.85-87 As a result, many researchers are currently investigating how exosomes can be used as viral decoys. Viral decoys have been previously used for HIV-1 with T cell membrane-coated nanoparticles,88 for adenovirus-37 with sulfated glycosaminoglycans,89 and for A disintegrin and metalloprotease domain-containing protein 10 (ADAM10)-expressing exosomes with methicillin-resistant staphylococcus aureus.90 Recently, nanodecoys or decoy cells have been considered for SARS-CoV-2 by engineering cells that do not replicate and present immunogenic antigens.91,92 However, exosomes are the most logical choice for acting as a viral decoy because their membrane proteins already reflect those in their parent cells, which can include the ACE2 receptor, which is what SARS-CoV-2 uses for viral entry.2,5,7,9,12,80 In May 2020, the idea of modifying exosome membranes to increase ACE2 and using the receptor to trick the virus into entering exosomes instead of cells was proposed.93 This could be a very effective method since using lung cell-derived exosomes would increase targeting to the lung. Furthermore, if exosome cargo was also engineered to include an antiviral drug to destroy the virus once trapped, the virus would not be able to infect host cells if exosomes released them.

Current nanoparticles used for drug delivery have problems with biocompatibility, structural heterogeneity, maintaining stability and solubility for delivery, avoiding clearance, reaching target regions, and result in low specificity and high toxicity.76 Frequently, nanoparticles for delivering chemotherapeutics depend on the enhanced permeability and retention (EPR) effect, but this is a passive and slow process. Exosomes have demonstrated biocompatibility and low immunogenicity, and exosomes are able to cross the blood-brain barrier.78 More importantly, because exosomes are the body’s mechanism for cell signaling, exosomes naturally target specific tissues. Therefore, exosomes have been investigated for targeted drug delivery, especially since it was found that using exosomes to deliver paclitaxel for treating multiple drug resistance cancer enhanced paclitaxel potency.94 Exosomes that carry and deliver antiviral drugs to COVID-19 or other virus-infected patients have potential to be a safe, strong-acting therapeutic.

4.2. LNPs as a drug delivery platform

When considering antiviral drugs, a delivery platform is required, because antivirals face many challenges once administered including crossing the blood-brain barrier and maintaining stability and efficacy upon dilution. One solution is in lipid nanoparticles, which are biocompatible and protect the drug during transport.95,96 LNPs are especially useful for drug delivery because their nanoscale size enables access into cells to release the unaltered cargo.97 Unfortunately, an important consideration with LNPs is the rate at which the drugs are released, with Naahidi et al. noting that sometimes, LNPs may release the drug at a rate that is too low to produce an effect.98 Previously, we described using LNPs to deliver mRNA that would produce proteins that induce an immune reaction against SARS-CoV-2, but LNPs can also package mRNA as a COVID-19 treatment, as well as antivirals and proteins to combat COVID-19. For instance, Kim et al. used mRNA-LNPs to induce cells to produce soluble human ACE2, which bound to SARS-CoV-2 and inhibited SARS-CoV-2 pseudovirus infection.99 LNPs have also been noted for carrying antiviral drugs, such as azidothymidine (AZT) and (S)-1-(3-Hydroxy-2-phsophonylmethoxypropyl)cytosine (HPMPC), to inhibit viral replication in HIV and herpes simplex virus (HSV), respectively.100,101 Some FDA approved treatments using LNPs to package and deliver drugs include Doxil Caelyx and Myocet— or LNP encapsulated doxorubicin—for various cancers, Marqibo—or LNP encapsulated vincristine—for various cancers, and Mepact—or LNP encapsulated mifamurtide—for osteosarcomas.102,103 Moreover, as an antiviral for flavivirus dengue virus, Croci et al. used LNPs to encapsulate and reduce the cytotoxicity of ivermectin, which has recently been proposed for COVID-19 treatment due to its efficacy against both RNA and DNA viruses.104,105 Another application of LNPs is as a drug carrier for remdesivir, which has shown efficacy against COVID-19 in vitro and in COVID-19 patients in clinical trials.106,107 Therefore, LNPs offer a safe and effective way to deliver and preserve the potency of COVID-19 drugs.

5. Conclusion

Since the advent of SAR-CoV-2, researchers have come together in a global effort and tirelessly pursued vaccine and therapeutic options, considering repurposing current drugs or creating new ones. According to clinicaltrials.gov, there are 266 vaccine studies with 62 currently in Phase III, meaning that these vaccines have demonstrated both safety and efficacy and are now being tested for comparison against placebo vaccinations.108 Candidates from each type of vaccine described in this review have reached Phase III, illustrating the potential for each and the potential for a SARS-CoV-2 vaccine to become available soon. In fact, if Moderna’s vaccine passes Phase III, the US Department of Health and Human Services has estimated that by April, there will be enough doses to treat all Americans.109 As for therapeutics, the innate regenerative properties and ability to carry drugs to targeted locations without causing immunogenicity or other undesirable side effects makes exosomes a prime therapeutic.75,76 Therefore, we believe exosomes hold the potential as a nanomedicine drug carrier to deliver COVID-19 therapeutics.110

Figure 1. Nanobiomedical vaccine approaches for SARS-CoV-2.

Figure 1.

The vaccine mechanisms of whole inactivated viruses (WIVs), self-assembled protein nanoparticles (NPs), adeno-associated viruses (AAVs), virus-like particles (VLPs), and mRNA-encapsulated lipid nanoparticles (mRNA-LNPs) for activating humoral and cellular immune responses.

Table 1. Applications of Different Vaccine Types.

Examples of pre-clinical and clinical applications for which whole inactivated viruses (WIVs), adeno-associated viruses (AAVs), virus-like particles (VLPs), and mRNA-encapsulated lipid nanoparticles (mRNA-LNPs) have been used.

Vaccination
Method
Disease Stage Citation
WIVs Poliovirus FDA Approved Karch et al. (2016)15
Hepatitis A FDA Approved Herk et al. (2005)23
Rabies FDA Approved States et al. (1998)24
Influenza FDA Approved Statler et al. (2019)25
MERS-CoV Pre-Clinical Deng et al. (2018)22
SARS-CoV-1 Pre-Clinical Spruth et al. (2006)18
SARS-CoV-2 Phase III Zhang et al. (2020)27
AAVs Lipoprotein Lipase Deficiency EMA Approved Santiago-Ortiza et al. (2016)31
Leber Congenital Amaurosis FDA Approved Wang et al. (2019)29
HIV-1 Pre-Clinical Lin et al. (2018)28
Influenza Pre-Clinical Demminger et al. (2020)34
SARS-CoV-1 Pre-Clinical Du et al. (2008)33
SARS-CoV-2 Phase III Logunev et al. (2020)36
Folegatti et al. (2020)37
VLPs HPV FDA Approved Wang et al. (2013)45
Flaviviruses Phase I Ramanathan et al. (2018)66
Influenza Pre-Clinical McCraw et al. (2018)52
Buffin et al. (2019)54
MERS-CoV-1 Pre-Clinical Wang et al. (2017)6
SARS-CoV-1 Pre-Clinical Lu et al. (2007)1
mRNA-LNPs HIV-1 Pre-Clinical Pardi et al. (2019)72
Flaviviruses Pre-Clinical Richner et al. (2017)71
Influenza Phase I Bahl et al. (2017)63
SARS-CoV-2 Phase III Zhang et al. (2020)2
Wang et al. (2020)9
Walsh et al. (2020)74

Acknowledgements

K.C. is supported by grants from the National Institutes of Health (HL123920, HL137093, HL144002, HL146153, HL147357, HL149940) and the American Heart Association (18TPA34230092 and 19EIA34660286). The content presented is solely the responsibility of the authors and does not represent the official views of the funding agencies

Biography

graphic file with name nihms-1664586-b0001.gif

Halle Lutz received her Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill with minors in Chemistry and Chinese. She is now in the combined DVM/PhD program at NC State University. Her research currently focuses on the treatment of heart and lung diseases using stem cells.

graphic file with name nihms-1664586-b0002.gif

Kristen Popowski received her B.S. in Animal Science from the University of Massachusetts, Amherst and is currently at completing her Ph.D. North Carolina State University in Comparative Biomedical Sciences. Her research interests include exosomes as a nanoparticle delivery system for lung regenerative medicine.

graphic file with name nihms-1664586-b0003.gif

Phuong-Uyen Dinh is a postdoctoral research scholar and the Lung Group Research Director within the Biotherapeutics Lab led by Dr. Ke Cheng. She received her B.S. in Biology from the University of North Carolina Greensboro and her Ph.D. in Comparative Biomedical Sciences from North Carolina State University. Her research focus is on utilizing biomedical approaches to developing cellular and acellular therapeutics for lung diseases using stem cells, exosomes, and biomaterials.

graphic file with name nihms-1664586-b0004.gif

Ke Cheng is a Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine in the Department of Molecular Biomedical Sciences at NC State University and in the UNC/NCSU Joint Department of Biomedical Engineering. He is an adjunct professor at the UNC Eshelman School of Pharmacy. He also serves as the co-director of the functional tissue engineering program at the Comparative Medicine Institute.

Footnotes

Conflict of Interest Statement

The authors declare no competing interests.

References

  • 1.Lu X, Chen Y, Bai B, Hu H, Tao L, Yang J, Chen J, Chen Z, Hu Z & Wang H. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 2007, 122, 496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zhang N, Li X, Deng Y, Wang Y, Ying B, Qin C, Zhang N, Li X, Deng Y, Zhao H, Huang Y, Yang G & Huang W. A Thermostable mRNA Vaccine against COVID-19. Cell 2020, 1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Te Tseng C, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ & Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012, 7,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, Chen J, Ward JM, Vassilev V & Subbarao K. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 2010, 23, 509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pinky S. Gupta, Krishnakumar V, Sharma Y, Dinda AK & Mohanty S. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19. Stem Cell Rev. Reports 2020, doi: 10.1007/s12015-020-10002-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wang C, Zheng X, Gai W, Zhao Y, Wang H, Wang H, Feng N, Chi H, Qiu B, Li N, Wang T, Gao Y, Yang S & Xia X. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 2017, 8, 12686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tsuchiya A, Takeuchi S, Iwasawa T, Kumagai M, Sato T, Motegi S, Ishii Y, Koseki Y, Tomiyoshi K, Natsui K, Takeda N, Yoshida Y, Yamazaki F, Kojima Y, Watanabe Y, Kimura N, Tominaga K, Kamimura H, Takamura M & Terai S. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Inflamm. Regen 2020, 40, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization; https://covid19.who.int/ (2020). [Google Scholar]
  • 9.Wang F, Kream RM & Stefano GB. An evidence based perspective on mRNA-SARScov-2 vaccine development. Med. Sci. Monit 2020, 26, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jeong H & Seong BL. Exploiting virus-like particles as innovative vaccines against emerging viral infections. J. Microbiol 2017, 55, 220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Huang X, Wang X, Zhang J, Xia N & Zhao Q. Escherichia coli-derived virus-like particles in vaccine development. npj Vaccines 2017, 2, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hassanpoura M, Rezaied J, Nouria M & Panahi Y. The role of extracellular vesicles in COVID-19 virus infection. Infect. Genet. Evol 2020, 85, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huang L, Rong Y, Pan Q, Yi K, Tang X, Zhang Q, Wang W, Wu J & Wang F. SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian J. Pharm. Sci 2020, doi: 10.1016/j.ajps.2020.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O’Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D & King NP. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell 2020, 1367 doi: 10.1016/j.cell.2020.10.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Karch CP & Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem. Pharmacol 2016, 120, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Plotkin S. History of vaccination. Proc. Natl. Acad. Sci. U. S. A 2014, 111, 12283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Thomas F & Magill TP. Vaccination of Human Subjects with Virus of Human Influenza. Proc. Soc. Exp. Biol. Med 1936, 33, 604. [Google Scholar]
  • 18.Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Brühl P, Grillberger L, Reiter M, Tauer C, Mundt W & Barrett PN. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006, 24, 652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Enjuanes L, Zuñiga S, Castaño-Rodriguez C, Gutierrez-Alvarez J, Canton J & Sola I. Molecular Basis of Coronavirus Virulence and Vaccine Development. Adv. Virus Res 2016, 96, 246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Tsunetsugu-yokota Y. Coronavirus Virions for Vaccine Antigen. Methods Mol. Biol 2008, 454, 119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M & Baric RS. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge. J. Virol 2011, 85, 12201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C & Tan W. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg. Microbes Infect 2018, 7,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Van Herck K & Van Damme P. Prevention of hepatitis A by Havrix(TM): a review. Expert Rev. Vaccines 2005, 4, 459. [DOI] [PubMed] [Google Scholar]
  • 24.RabAvert: new human rabies vaccine approved in the United States. Int. J. Trauma Nurs 1998, 4, 58. [DOI] [PubMed] [Google Scholar]
  • 25.Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J & Marshall GS. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6–59 months of age: A phase 3, randomized, noninferiority study. Vaccine 2019, 37, 343. [DOI] [PubMed] [Google Scholar]
  • 26.Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W & Yang X. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell 2020, 182, 713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q & Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis 2020, 0,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lin A & Balazs AB. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1. Retrovirology 2018, 15, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wang DP, Tai WL & Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019, 18, 358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Naso MF, Tomkowicz B, Perry WL & Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs 2017, 31, 317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Santiago-Ortiza JL & Schaffer DV. Adeno-Associated Virus (AAV) Vectors in Cancer Gene Therapy. J. Control. Release 2016, 240, 287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yusuf Y, Yoshii T, Iyori M, Yoshida K, Mizukami H, Fukumoto S, Yamamoto DS, Alam A, Bin Emran T, Amelia F, Islam A, Otsuka H, Takashima E, Tsuboi T & Yoshida S. Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming. Front. Immunol 2019, 10, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y & Zheng BJ. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-. J. Immunol 2008, 180, 948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Demminger DE, Walz L, Dietert K, Hoffmann H, Planz O, Gruber AD, Messling V & Wolff T. Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies. EMBO Mol. Med 2020, 12, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hocquemiller M, Giersch L, Audrain M, Parker S & Cartier N. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum. Gene Ther 2016, 27, 478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, E.A. [Google Scholar]
  • 37.Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC & Pollard AJ. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Callaway E. Russia announces positive COVID-vaccine results from controversial trial. Nature 2020, doi: 10.1038/d41586-020-03209-0. [DOI] [PubMed] [Google Scholar]
  • 39.Balakrishnan VS. The arrival of Sputnik V. Lancet. Infect. Dis 2020, 20, 1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Porter KR & Thompson HP. A particulate body associated with epithelial cells cultured from mammary carcinomas of mice of a milkfactor strain. J. Exp. Med 1948, 88, 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mohsen MO, Zha L, Cabral-Miranda G & Bachmann MF. Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin. Immunol 2017, 34, 123. [DOI] [PubMed] [Google Scholar]
  • 42.Frietze KM, Peabody DS & Chackerian B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol 2016, 18, 44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Mohsen MO, Speiser DE, Knuth A & Bachmann MF. Virus-like particles for vaccination against cancer. Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology 2020, 12, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rohovie MJ, Nagasawa M & Swartz JR. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng. Transl. Med 2017, 2, 43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wang JW & Roden RBS. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev. Vaccines 2013, 12, 129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Jackman JA, Yoon BK, Ouyang L, Wang N, Ferhan AR, Kim J, Majima T & Cho N. Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines. Adv. Funct. Mater. 2020, 2008352, 2008352. [Google Scholar]
  • 47.Zeltins A. Construction and characterization of virus-like particles: A review. Mol. Biotechnol 2013, 53, 92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Syomin BV & Ilyin YV. Virus-Like Particles as an Instrument of Vaccine Production. Mol. Biol 2019, 53, 323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Maphis NM, Peabody J, Crossey E, Jiang S, Jamaleddin Ahmad FA, Alvarez M, Mansoor SK, Yaney A, Yang Y, Sillerud LO, Wilson CM, Selwyn R, Brigman JL, Cannon JL, Peabody DS, Chackerian B & Bhaskar K. Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy. npj Vaccines 2019, 4,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zeltins A, West J, Zabel F, El TurabiI A. Balke S. Haas, Maudrich M, Storni F, Engeroff P, Jennings GT, Kotecha A, Stuart DI, Foerster J & Bachmann MF. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. npj Vaccines 2017, 2, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hu X, Deng Y, Chen X, Zhou Y, Zhang H, Wu H, Yang S, Chen F, Zhou Z, Wang M, Qiu Z & Liao Y. Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine. Sci. Rep 2017, 7, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Azegami T & Itoh H. Vaccine Development against the Renin-Angiotensin System for the Treatment of Hypertension. Int. J. Hypertens 2019, 2019,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ou X, Guo L, Wu J, Mi K, Yin N, Zhang G, Li H & Sun M. Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle. Hum. Vaccines Immunother 2013, 9, 1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Maurer PG, Jennings T, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Müller P & Bachmann MF. A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and phase I safety and immunogenicity. Eur. J. Immunol 2005, 35, 2031. [DOI] [PubMed] [Google Scholar]
  • 55.Cavelti-Weder CK, Timper E. Seelig, Keller C, Osranek M, Lssing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY & Bachmann MF. Development of an interleukin-1β vaccine in patients with type 2 diabetes. Mol. Ther 2016, 24, 1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Kratzer B, Hofer S, Zabel M & Pickl WF. All the small things: How virus-like particles and liposomes modulate allergic immune responses. Eur. J. Immunol 2020, 50, 17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Metz SW, Thomas A, White L, Stoops M, Corten M, Hannemann H & De Silva AM. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol. J 2018, 15, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Liu Y, Massare VMJ, Barnard DL, Kort T, Nathan M, Wang L & Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 2011, 29, 6606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Boigard H, Cimica V & Galarza JM. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature. Vaccine 2018, 36, 7728. [DOI] [PubMed] [Google Scholar]
  • 60.McCraw DM, Gallagher JR, Torian U, Myers ML, Conlon MT, Gulati NM & Harris AK. Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization. Sci. Rep 2018, 8, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Kim SM, Kim YI, Park SJ, Kim EH, Kwon H, Si YJ, Lee IW, Song MS & Ki Y. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. J. Virol 2017, 91, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Buffin S, Peubez I, Barrière F, Nicolaï MC, Tapia T, Dhir V, Forma E, Sève N & Legastelois I. Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies. Vaccine 2019, 37, 6857. [DOI] [PubMed] [Google Scholar]
  • 63.Bahl KJ, Senn J, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, Ribeiro A, Watson M, Zaks T & Ciaramella G. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther 2017, 25, 1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pierson TC & Diamond MS. The continued threat of emerging flaviviruses. Nat. Microbiol 2020, 5, 796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Rossmann MG, Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS & Strauss JH. Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Sel. Pap. Michael G Rossmann with Comment 2014, 108, 317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, Maclaren G & Brodie D. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 2018, 391, 552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Chen H, Huang C, Lin S & Fang Z. Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection. Biomaterials 2016, 106, 111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Liang F, Lindgren G, Lin A, Thompson EA, Ols S, Röhss J, John S, Hassett K, Yuzhakov O, Bahl K, Brito LA, Salter H, Ciaramella G & Loré K. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol. Ther 2017, 25, 2635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Garber K. Alnylam launches era of RNAi drugs. Nat. Biotechnol 2018, 36, 777. [DOI] [PubMed] [Google Scholar]
  • 70.McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, Zhou J, Bouton CR, Rogers P, Polra K, Lin PJC, Barbosa C, Tam YK, Barclay WS & Shattock RJ. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun 2020, 11, 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G & Diamond MS. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 2017, 169, 176. [DOI] [PubMed] [Google Scholar]
  • 72.Pardi NC, LaBranche C, Ferrari G, Cain DW, Tombácz I, Parks RJ, Muramatsu H, Mui BL, Tam YK, Karikó K, Polacino P, Barbosa CJ, Madden TD, Hope MJ, Haynes BF, Montefiori DC, Hu SL & Weissman D. Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Mol. Ther. - Nucleic Acids 2019, 15, 36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.VanBlargan LA, Himansu S, Foreman BM, Ebel GD, Pierson TC & Diamond MS. An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections. Cell Rep. 2018, 25, 3382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi P-Y, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U & Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med 2020, 1 doi: 10.1056/nejmoa2027906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Popowski K, Lutz H, Hu S, George A, Dinh PU & Cheng K. Exosome therapeutics for lung regenerative medicine. J. Extracell. Vesicles 2020, 9,. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Lutz H, Hu S, Dinh PU & Cheng K. Cells and cell derivatives as drug carriers for targeted delivery. Med. Drug Discov. 2019, 3, 100014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Sun MK, Passaro AP, Latchoumane CF, Spellicy SE, Bowler M, Goeden M, Martin WJ, Holmes PV, Stice SL & Karumbaiah L. Extracellular Vesicles Mediate Neuroprotection and Functional Recovery after Traumatic Brain Injury. J. Neurotrauma 2020, 37, 1358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Zhang D, Lee H, Wang X, Rai A, Groot M & Jin Y. Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses. Mol. Ther. 2018, 26, 2119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Dinh PUC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, Huang K, Hensley MT, Harrell E, Vandergriff AC, George AK, Barrio RT, Hu S, Allen TA, Blackburn K, Caranasos TG, Peng X, Schnabel LV, Adler KB, Lobo LJ, Goshe MB & Cheng K. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun 2020, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A & Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020, 29, 747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Ruijin Hospital. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia. clinicaltrials.gov(2020) doi:NCT04276987.
  • 82.Ruijin Hospital. A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS. clinicaltrials.gov(2020) doi:NCT04602104.
  • 83.Henry E, Cores J, Hensley MT, Anthony S, Vandergriff A, de Andrade JBM, Allen T, Caranasos TG, Lobo LJ & Cheng K. Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis. Stem Cells Transl. Med 2015, 4, 1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Cores J, Dinh PUC, Hensley T, Adler KB, Lobo LJ & Cheng K. A pre-investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis. Stem Cells Transl. Med 2020, 9, 786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Duong N, Curley K, Brown A, Campanelli A, Do MA, Levy D, Tantry A, Marriott G & Lu B. Decoy exosomes as a novel biologic reagent to antagonize inflammation. Int. J. Nanomedicine 2019, 14, 3413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Qiao L, Hu S, Huang K, Su T, Li Z, Vandergriff A, Cores J, Dinh PU, Allen T, Shen D, Liang H, Li Y & Cheng K. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics 2020, 10, 3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Liang H, Huang K, Su T, Li Z, Hu S, Dinh U, Wrona EA, Shao C, Qiao L, Vandergriff AC, Taylor M, Cores J, Allen T, Zhang H, Zeng Q, Xing J, Freytes DO, Shen D, Yu Z & Cheng K. Mesenchymal stem cell/red blood cell-inspired nanoparticle therapy in mice with carbon tetrachloride-induced acute liver failure. ACS Nano 2019, 12, 6536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Wei X, Zhang G, Ran D, Krishnan N, Fang RH, Gao W, Spector SA & Zhang L. T-Cell-Mimicking Nanoparticles Can Neutralize HIV Infectivity. Adv. Mater 2018, 30, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Chandra N, Liu Y, Liu JX, Frängsmyr L, Wu N, Silva LM, Lindström M, Chai W, Domellöf FP, Feizi T & Arnberg N. Sulfated glycosaminoglycans as viral decoy receptors for human adenovirus type 37. Viruses 2019, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Keller MD, Ching KL, Liang FX, Dhabaria A, Tam K, Ueberheide BM, Unutmaz D, Torres VJ & Cadwell K. Decoy exosomes provide protection against bacterial toxins. Nature 2020, 579, 260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Ji H, Yan Y, Ding B, Guo W, Brunswick M & Niethammer A. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS- CoV-2 virus. Med. Drug Discov 2020, 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC & Tao W. A materials-science perspective on tackling COVID-19. Nat. Rev. Mater 2020, 5, 847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Inal JM. Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clin. Sci 2020, 134, 1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV & Batrakova EV. Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells. Nanomedicine 2016, 12, 655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Nikaeen G, Abbaszadeh S & Yousefinejad S. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses. Nanomedicine 2020, 15, 1501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Gurunathan S, Qasim M, Choi Y, Do JT, Park C, Hong K, Kim JH & Song H. Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses? Nanomaterials 2020, 10, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Chen Z, Wang Z & Gu Z. Bioinspired and Biomimetic Nanomedicines. Acc. Chem. Res 2019, doi: 10.1021/acs.accounts.9b00079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A & Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J. Control. Release 2013, 166, 182. [DOI] [PubMed] [Google Scholar]
  • 99.Kim J, Mukherjee A, Nelson D, Jozic A & Sahay G. Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2. bioRxiv 2020, doi: 10.1101/2020.07.24.205583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Phillips N & Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992, 79, 1137. [PubMed] [Google Scholar]
  • 101.Korvasová Z, Drašar L, Mašek J, Knotigová PT, Kulich P, Matiašovic J, Kovařčík K, Bartheldyová E, Koudelka Š, Škrabalová M, Miller AD, Holý A, Ledvina M & Turánek J. Antiviral effect of HPMPC (Cidofovir®), entrapped in cationic liposomes: In vitro study on MDBK cell and BHV-1 virus. J. Control. Release 2012, 160, 330. [DOI] [PubMed] [Google Scholar]
  • 102.Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, Zhao W, Leow CC & Hollingsworth R. Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia (United States) 2015, 17, 661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Anselmo AC & Mitragotri S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med 2019, 4, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Croci R, Bottaro E, Chan KWK, Watanabe S, Pezzullo M, Mastrangelo E & Nastruzzi C. Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin. Int. J. Biomater 2016, 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Heidary F & Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J. Antibiot. (Tokyo) 2020, 73, 593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S & Lane HC. Remdesivir for the Treatment of Covid-19 — Final Report. N. Engl. J. Med 2020, 383, 1813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R & Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med 2020, 382, 2327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.ClinicalTrials.gov. NIH U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/results?term=vaccine&cond=Covid19&age_v=&gndr=&type=&rslt=&phase=2&Search=Apply. [DOI] [PubMed]
  • 109.Ducharme J. COVID-19 Vaccine Should Be Available to the General Public by April 2021, Health Officials Say. TIME 2020. [Google Scholar]
  • 110.Qiao L, Li Y & Cheng K. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. The Journal of Clinical Investigation. J Clin Invest 2019, 129, 2237. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES